Sweet Harmony: Neuro biotech buys Epygenix and its epilepsy meds for $35M upfront

Harmony Biosciences is adding a suite of epilepsy assets to its pipeline, buying Epygenix for $35 million upfront with more than $600 million in biobucks on the table.